Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Recent patents report discovery of novel antidiabetic agents

Aug. 6, 2008

Amicus successfully completes end of phase II meeting with FDA for Amigal

Aug. 5, 2008

Patents reveal discovery of compounds for metabolic disorders

Aug. 4, 2008

PYY(3-36) for obesity does not meet primary efficacy endpoint in phase II study

Aug. 4, 2008

Karo Bio reports positive results from phase IIb study with eprotirome in dyslipidemia

Aug. 4, 2008

AtheroGenics reports positive results from phase III ANDES trial in diabetes

Aug. 1, 2008

Cytochroma and Mitsubishi Tanabe sign a U.S. and Asian license agreement for CTA-018

Aug. 1, 2008

Novel antidiabetic agents claimed in recent patents

July 30, 2008

Once-yearly Aclasta recommended for approval in E.U. for male osteoporosis

July 29, 2008

Amgen reports positive results from phase III trial of denosumab in osteoporosis

July 28, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
NTX-819, a novel mGlu7 NAM for psychiatric disorders
BioWorld Science
Increasing evidence supports metabotropic glutamate mGlu7 receptor as a promising target in psychiatric disorders. Neurosterix Pharma Sarl has presented data on...